Survival forests associate clinical and treatment-plan features with glioma survival
Source check: Source checked. Not independent scientific confirmation.
Finding: A retrospective 95-patient high-grade glioma study used random survival forests to relate clinical characteristics and radiotherapy dose-volume features to observed survival. Age, tumor volume, grade, performance status, IDH status and a dose-coverage feature were selected by the learned model. This is an exploratory cohort association; the study does not establish that changing radiation dose improves survival or that its prediction performance generalizes to new hospitals.
Technology: Random survival forest; support-vector-machine comparison
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The survival forest learns nonlinear relationships between clinical/dose-volume features and survival, selecting a multifeature risk representation for retrospective outcome analysis.
- Test and result
- The source analyzes 95 historical patients, randomly dividing 57 for model development and 38 for testing. The survival forest selects clinical factors and a treatment-plan dose-coverage feature associated with recorded outcomes.
- Limitation / still unknown
- Continuous variables were converted using outcome-optimized cut points before the described split; preprocessing isolation is not established, so reported test accuracy may be optimistic. Feature selection and small-cohort risk thresholds need validation. Treatment choices, tumor size and case mix can confound dose–survival relationships. Decision-curve analysis is model-based, not demonstrated clinical utility, and no causal dose-prescription guidance follows.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/PMC8026951/unicode
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact primary BioC document ID and article-front DOI/title/PMID; clinical/statistical model Methods and survival Results/limitations. Current primary notice metadata checked; treatment instructions are not represented..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.